Learning from mistakes in clinical practice guidelines: The case of perioperative β-blockade

BMJ Quality and Safety

Volumn 23, Issue 11, 2014, Pages 957-964

  Neuman, Mark D ^a,b   Bosk, Charles L ^a,b   Fleisher, Lee A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PLACEBO;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; LEARNING; MEDICAL DECISION MAKING; MEDICAL ERROR; PATIENT SAFETY; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL MORTALITY; SURGICAL PATIENT; SURGICAL RISK; SURVIVAL; VASCULAR SURGERY; CARDIOVASCULAR DISEASES; HISTORY; POSTOPERATIVE COMPLICATIONS; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84907315579     PISSN: 20445415     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmjqs-2014-003114     Document Type: Article

References (71)

1. Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713-20.
2. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-94.
3. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-47.
4. Brady AR, Gibbs JS, Greenhalgh RM, et al. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. J Vasc Surg 2005;41:602-9.
5. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 2006;332:1482.
6. Yang H, Raymer K, Butler R, et al. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006;152:983-90.
7. Shojania KG, Duncan BW, Mcdonald KM, et al. Making health care safer: a critical analysis of patient safety practices (Evidence Report/Technology Assessment, No. 43). Rockville, MD: U.S. Agency for Healthcare Quality and Research, 2001:1-8.
8. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery - Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 2002;94:1052-64.
9. Shekelle PG, Wachter RM, Pronovost PJ, et al. Making health care safer II: an updated critical analysis of the evidence for patient safety practices. (Evidence Report No. 211.). Rockville, MD: U.S. Agency for Healthcare Research and Quality, 2013:169-71.
10. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol 2009;54:e13-118.
11. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage, 2005.
12. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011;364:476-80.
13. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845-50.
14. Neuman MD, Bosk CL. What we talk about when we talk about risk: refining surgery's hazards in medical thought. Milbank Q 2012;90:135-59.
15. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 1996;27:910-48.
16. Marks H. The progress of experiment: science and therapeutic reform in the United States, 1900-1990. Cambridge: Cambridge University Press, 1997.
17. Daly J. Evidence based medicine and the search for a science of clinical care. Berkeley, CA: University of California Press, 2005.
18. Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 1997;127:313-28.
19. American College of Physicians. Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. Ann Intern Med 1997;127:309-12.
20. Podolsky D, Beddingfield KT. Rx for Deaths after Surgery. U.S. News and World Report, 1996:75.
21. Warltier DC. Beta-adrenergic-blocking drugs: incredibly useful, incredibly underutilized. Anesthesiology 1998;88:2-5.
22. Sutton T, Rock P. Pro: beta-blockers should be used in all patients undergoing vascular surgery. J Cardiothorac Vasc Anesth 1999;13:490-5.
23. Leung JM. Diabetes and not lack of treatment with atenolol predicts decreased survival after noncardiac surgery. Anesthesiology 1999;90:1226-7.
24. Petros JA. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1997;336:1452; author reply 53-4.
25. Lustik SJ, Chhibber AK, Eichelberger JP. Effects of atenolol on postoperative myocardial ischemia. Anesthesiology 1998;89:794-5.
26. Howell SJ, Sear JW, Foex P. Peri-operative beta-blockade: a useful treatment that should be greeted with cautious enthusiasm. Br J Anaesth 2001;86:161-4.
27. Auerbach AD, Goldman L. beta-Blockers and reduction of cardiac events in noncardiac surgery: clinical applications. JAMA 2002;287:1445-7.
28. Auerbach AD, Goldman L. beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 2002;287:1435-44.
29. Feldman T, Fusman B, McKinsey JF. Beta-blockade for patients undergoing vascular surgery. N Engl J Med 2000;342:1051-2; author reply 52-3.
30. Fleisher LA, Eagle KA. Clinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med 2001;345:1677-82.
31. Lee TH. Reducing cardiac risk in noncardiac surgery. N Engl J Med 1999;341:1838-40.
32. Selzman CH, Miller SA, Zimmerman MA, et al. The case for beta-adrenergic blockade as prophylaxis against perioperative cardiovascular morbidity and mortality. Arch Surg 2001;136:286-90.
33. Cina RA, Froehlich JB, Hamdan AD. Perioperative beta-blockade to reduce cardiac morbidity in noncardiac surgery. Int Anesthesiol Clin 2001;39:93-104.
34. Leape LL, Berwick DM, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA 2002;288:501-7.
35. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002;39:542-53.
36. Birkmeyer JD, Dimick JB. Potential benefits of the new Leapfrog standards: effect of process and outcomes measures. Surgery 2004;135:569-75.
37. Brooke BS, Dominici F, Makary MA, et al. Use of beta-blockers during aortic aneurysm repair: bridging the gap between evidence and effective practice. Health Aff (Millwood) 2009;28:1199-209.
38. Lindenauer PK, Fitzgerald J, Hoople N, et al. The potential preventability of postoperative myocardial infarction: underuse of perioperative beta-adrenergic blockade. Arch Intern Med 2004;164:762-6.
39. Schmidt M, Lindenauer PK, Fitzgerald JL, et al. Forecasting the impact of a clinical practice guideline for perioperative beta-blockers to reduce cardiovascular morbidity and mortality. Arch Intern Med 2002;162:63-9.
40. Wijeysundera DN, Mamdani M, Laupacis A, et al. Clinical evidence, practice guidelines, and beta-blocker utilization before major noncardiac surgery. Circ Cardiovasc Qual Outcomes 2012;5:558-65.
41. Grayburn PA, Hillis LD. Cardiac events in patients undergoing noncardiac surgery: shifting the paradigm from noninvasive risk stratification to therapy. Ann Intern Med 2003;138:506-11.
42. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005;331:313-21.
43. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005;353:349-61.
44. Fleisher LA, Poldermans D. Perioperative beta blockade: where do we go from here? Lancet 2008;371:1813-14.
45. Riedel B, Shaw A, Le Manach Y, et al. Beta-blocker therapy in non-cardiac surgery. Lancet 2008;372:1146-7.
46. Keane M. Beta-blocker therapy in non-cardiac surgery. Lancet 2008;372:1145; author reply 46.
47. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. J Am Coll Cardiol 2006;47:2343-55.
48. Erasmus Medical Center. Erasmus MC dismisses professor. November 17, 2011 ed. Rotterdam, 2011.
49. Chopra V, Eagle KA. Perioperative mischief: the price of academic misconduct. Am J Med 2012;125:953-5.
50. Bouri S, Shun-Shin MJ, Cole GD, et al. Meta-analysis of secure randomised controlled trials of beta-blockade to prevent perioperative death in non-cardiac surgery. Heart 2014;100:456-64.
51. Luscher TF, Gersh B, Landmesser U, et al. Is the panic about beta-blockers in perioperative care justified? Eur Heart J Published Online First: 6 Feb 2014. doi:10.1093/eurheartj/ehu056
52. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
53. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-9.
54. Jones DS. Visions of a cure. Visualization, clinical trials, and controversies in cardiac therapeutics, 1968-1998. Isis 2000;91:504-41.
55. Jones DS. Broken hearts: the tangled history of cardiac care. Baltimore, MD: Johns Hopkins University Press, 2012.
56. Inzucchi SE, Siegel MD. Glucose control in the ICU - how tight is too tight? N Engl J Med 2009;360:1346-9.
57. LaPar DJ, Isbell JM, Kern JA, et al. Surgical Care Improvement Project measure for postoperative glucose control should not be used as a measure of quality after cardiac surgery. J Thorac Cardiovasc Surg 2014;147:1041-8.
58. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
59. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
60. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006;355:1640-2.
61. Thachil J, Toh CH, Levi M, et al. The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation]. Br J Haematol 2012;157:493-4.
62. Antman EM, Lau J, Kupelnick B, et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992;268:240-8.
63. Gray BH, Gusmano MK, Collins SR. AHCPR and the changing politics of health services research. Health Aff (Millwood) 2003;Suppl Web Exclusives:W3-283-307.
64. Shojania KG, Sampson M, Ansari MT, et al. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 2007;147:224-33.
65. Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. JAMA 2012;307:37-8.
66. Neuman MD, Goldstein JN, Cirullo MA, et al. Durability of class I American College of Cardiology/American Heart Association clinical practice guideline recommendations. JAMA 2014;311:2092-100.
67. Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124.
68. Tonelli MR. Integrating evidence into clinical practice: an alternative to evidence-based approaches. J Eval Clin Pract 2006;12:248-56.
69. Neuman MD, Bosk CL. Medicine and the radiant city. Lancet 2013;381:1176-7.
70. Rothman KJ. Six persistent research misconceptions. J Gen Intern Med 2014;29:1060-4.
71. Tonelli MR, Curtis JR, Guntupalli KK, et al. An official multi-society statement: the role of clinical research results in the practice of critical care medicine. Am J Respir Crit Care Med 2012;185:1117-24.